Thermo Fisher Scientific, Inc announces a new strategic partnership with Megaware, a life science technology organisation, to deliver a new bioanalysis/equivalence solution and joint support services for pharmaceutical, biotech and Contract Research Organisations (CROs).
The two companies will market a new comprehensive end-to-end software solution which provides bioequivalence functionality on a single platform to help speed up and manage clinical trials. Rapid market
growth in generic drug production is driving the requirement for fast efficient bioequivalence studies to meet FDA ANDA guidelines (Abbreviated New Drug Applications). A unified software solution will
aggregate disparate software systems for organisations that demand tools to speed service and management of this critical and regulated IPO.
Thermo Fisher and Megaware will jointly sell, market and support the new solution in the field. Thermo Fisher will bring its bioanalytical expertise to the partnership and Megaware, with headquarters in
Westborough, MA and Mumbai, India, will deliver the end-to-end technological focus combined with on-the-ground market knowledge. The new solution will offer higher throughput, greater levels of compliance
and standardisation of bioequivalence processes.
Product directory
